Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00170950 · ClinicalTrials.gov registry record · Phase 3
Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension
A Phase 3 study, sponsored by Novartis.
- Terminated
- Registry status
- Phase 3
- Development phase
- 11,506
- Enrollment target
NCT00170950: Clinical Trial Phase 3 study, sponsored by Novartis.
NCT00170950 is a Phase 3 study that was terminated before completion, run by Novartis. The registered enrollment target is 11,506 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1392% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00170950, a Phase 3 study, was terminated before completion, sponsored by Novartis.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 11,506 participants
- Enrollment target
Study Summary
A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population.
Primary Outcome
CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes.
Interventions
- DRUG Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1
- DRUG Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2
- DRUG Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
- DRUG Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1
- DRUG Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,506 participants |
| Start Date | 2003-10 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
Why NCT00170950 stopped before completion
NCT00170950 is an interventional study that assigns participants to a tested intervention. Its 11,506 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1392% higher).
The record links to 0 conditions, and to 5 interventions - of which Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1 is the first listed.
NCT00170950 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00170950 about?
NCT00170950 is a clinical study titled "Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension". A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population.
What is the current status of trial NCT00170950?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 11,506 participants. The study started on 2003-10. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00170950?
The interventions under investigation include: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1 (DRUG), Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 (DRUG), Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter (DRUG), Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1 (DRUG), Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2 (DRUG).
Who is sponsoring clinical trial NCT00170950?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00170950's enrollment target sits among peer trials
11,506 21st of 2000 higher than 1,980 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06677060 · 11,300 participants · Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
- NCT07064473 · 11,800 participants · Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- NCT01772771 · 12,000 participants
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- NCT04937868 · 12,000 participants
Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia